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Background/Aims: The reappearance rates of hepatitis C virus (HCV) RNA after a sustained virological response (SVR) have 
been reported to be 1-2%. We investigated the reappearance rate of HCV RNA after SVR in chronic hepatitis C (CHC) patients 
treated with pegylated interferon (PEG-IFN) and ribavirin. Methods: In total, 292 CHC patients who achieved an SVR after 
PEG-IFN and ribavirin treatment were included. They were treated with subcutaneous injections of either PEG-IFN-α 2a or 2b 
plus ribavirin orally. Liver function tests and qualitative HCV RNA assays were performed every 6 months during the follow-up 
period after an SVR. Results: Among the 292 patients, 224 (genotype 1, 92; genotype non-1, 132) were followed up for more 
than 6 months after SVR. These 224 patients were aged 48.1±11.5 years (mean±SD), and 129 of them were male. The median 
follow-up duration was 18 months (range 6-60 months). The reappearance rate of HCV RNA during follow-up was 0%. Two 
patients who achieved an SVR developed hepatocellular carcinoma during the follow-up period. Conclusions: An SVR was 
maintained in all CHC patients treated with PEG-IFN plus ribavirin during a median follow-up of 18 months. However, a screening 
test for hepatocellular carcinoma is needed for patients with an SVR. (Korean J Hepatol 2011;17:183-188)
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INTRODUCTION
Globally, it has been estimated that 170 million people are 
chronically infected with the hepatitis C virus (HCV), and 3 to 4 
million are infected each year.
1,2 The HCV is a major public 
health problem and a leading cause of chronic liver disease.
3 
Natural history studies indicate that 55% to 85% of individuals 
who develop acute hepatitis C will remain HCV-infected.
4-6 The 
risk of developing cirrhosis ranges from 5% to 25% over periods 
of 25 to 30 years.
7,8
The currently recommended therapy for chronic HCV 
infection is the combination of pegylated interferon (PEG-IFN) 
and ribavirin.
9 The sustained virological response (SVR) rates in 
patients treated with PEG-IFN and ribavirin are 50% in HCV 
genotype 1 and 80-90% in HCV genotype 2 or 3.
9-12 The 
achievement of the SVR in patients with chronic hepatitis C 
(CHC) has been associated with improvements in liver histology 
as well as a reduced risk of hepatocellular carcinoma (HCC) and 
liver-related mortality.
13-15
Previous studies reported that the SVR after PEG-IFN and 
ribavirin combination therapy was maintained up to 99-100% 
during the long-term follow-up.
16-20 However, a Korean study 
recently reported that the reappearance rate of HCV RNA after 
SVR was as high as 11%.
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reappearance rate of HCV RNA after SVR in CHC patients 
treated with PEG-IFN and ribavirin. 
PATIENTS AND METHODS
Patients and treatments
Three hundred forty three consecutive patients with CHC 
were treated with PEG-IFN and ribavirin at Paik Hospital, 
Busan, Korea, between April 2004 and December 2008. Among 
them, 292 patients (85.1%) with SVR were included in this study.
They were treated with subcutaneous injections of either 
PEG-IFN-α 2a (Pegasys
®; F. Hoffmann-La Roche, Ltd., Basel, 
Switzerland), at a dose of 180 μg/week or PEG-IFN-α 2b (Peg-
Intron
®; Schering Plough Corp., Kenilworth, NJ), at a dose of 1.5
μg/kg/week and ribavirin orally. The ribavirin dose was 
determined according to the HCV genotype and the patients’ 
body weight, as follows: dose of 1,000 mg/day (for patients 
weighing ≤75 kg) or 1,200 mg/day (for patients weighing >75 
kg) in genotype 1 and 800-1,000 mg/day in genotype non-1. The 
standard treatment duration was 48 weeks in infections with the 
HVC genotype 1 and 24 weeks in those with the genotype non-1.
For the quantitative HCV-RNA assay, before February 2009, 
we used the Cobas Amplicor HCV Monitor Version 2.0 (Roche 
diagnostic, IN, USA), with the lower limit of detection of 600 
IU/mL. From February 2009, we used the Cobas Ampliprep/ 
Cobas TaqMan system (Roche Molecular Systems, Pleasanton, 
CA), with the lower limit of detection of 15 IU/mL. The HCV 
RNA was measured at baseline (i.e. before treatment) and during 
the treatment, at weeks 4 and 12. To assess the efficacy of the 
treatment, the qualitative HCV RNA assay (Cobas Amplicor 
HCV Test Version 2.0, Roche diagnostic, IN, USA, lower limit of 
detection, 50 IU/mL) was performed at the end of treatment and 
24 weeks after completing the therapy. HCV genotyping was 
performed in all patients before treatment initiation, using the 
INNO-LiPA HCV II kit (Bayer Diagnostics, Emeryville, CA). 
The dose of PEG-IFN was reduced to 75% of the initial dose if 
the neutrophil count decreased under 750/mm
3 or the platelet 
count were under 50,000/mm
3, the dose was reduced to 50% if 
there was no improvement of cytopenia, and the treatment with 
PEG-IFN was discontinued if the neutrophil count further 
decreased under 500/mm
3 or the platelet count decreased under 
30,000/mm
3. Ribavirin was reduced stepwise from the initial 
dose to 600 mg if the hemoglobin decreased under 10 g/dL, and 
was discontinued if the hemoglobin further decreased under 8 
g/dL. When medication-related adverse effects occurred, such as 
flu-like symptoms, depression or insomnia, non steroidal anti- 
inflammatory drugs, anti-depressant and hypnotics were administered 
to improve the patients' symptoms. During the follow-up period 
after SVR, qualitative HCV RNA assays and liver function tests 
were performed every 6 months. We called the patients lost to 
follow-up within the past one year and asked for checking their 
liver function and HCV RNA test.
Definitions of virological responses
Rapid virological response was defined as HCV RNA 
negative at treatment week 4 by a sensitive PCR based quantitative 
assay. Early virological response was defined as qualitative 
HCV RNA negative or a reduction from baseline HCV RNA 
level of 2 log10 IU/mL at week 12. End of treatment response 
and SVR were defined, respectively, as a negative qualitative 
HCV RNA level at the end of treatment and after 24 weeks of 
untreated follow-up.
Relapse was defined as reversion to HCV RNA positive status 
in patients who had an undetectable HCV RNA level at the end 
of treatment, and reappearance was defined as HCV RNA 
positive after SVR.
RESULTS
Among the 343 patients treated with PEG-IFN and ribavirin, 
the numbers of genotype 1 and non-1 patients were 151 and 
192, respectively. Three hundred thirty eight patients (98.5%) 
achieved the end of treatment response and 292 patients (85.1%) 
achieved the SVR. The SVR was 75.5% (114/151) in genotype 1 
and 92.7% (178/192) in genotype non-1. The numbers of patients 
who were followed-up with HCV RNA assays and liver function 
tests for more than 6 months after SVR were 224. Sixty five 
patients were lost to follow-up. The remaining three patients 
were less than 6 months of follow-up period, so they didn't 
perform HCV RNA assays. These 224 patients were actually 
followed-up for a median period of 18 months (range 6-60 
months). The baseline characteristics and treatment doses of the 
patients were shown in Table 1. During the follow-up period, 
ALT increased in 149 (66.5%) and was maintained within normal 
limits in 75 (33.5%). Pre-treatment abdominal ultrasonography 
was performed in 220 patients, 22/220 (10%) had liver cirrhosis 
and 196/220 (89.1%) did not. Two patients already had HCC. 
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Table 1. Baseline characteristics of the enrolled patients
Characteristics Patients (N=224)
Age (years) 48.1±11.5
Sex (M:F) 129:95
Genotype (1:non-1) 92:132
ALT (IU/L) 98.9±110.8
BMI (kg/m
2) 23.2±2.5
HCV RNA (copies/mL) 4.3±5.2×10
6
RVR (%, n) 83.3 (184/221)
Naive/Re-treat 214:10
Abdominal USG (%, n)
  No liver cirrosis
  Liver cirrhosis
  HCC
89.1 (196/220)
10.0 (22/220)
0.9 (2/220)
Peginterferon dose (%, n)
  ≥80
  60≤ <80
  <60
52.7 (118/224)
22.8 (51/224)
24.5 (55/224)
Ribavirin dose (%, n)
  ≥80
  60≤ <80
  <60
59.4 (133/224)
26.8 (60/224)
13.8 (31/224)
ALT, alanine aminotransferase; BMI, body mass index; HCV, 
hepatitis C virus; HCC, hepatocellular carcinoma; RVR, rapid 
virological response.
343 chronic hepatitis C patients  were treated 
with pegylated interferon and ribavirin
SVR (N=292, 85.1%)
Genotype-1: 75.5%( 114/151), non-1:92.7%(178/192)
Follow up ≥ 6months after SVR (N=224)
Genotype-1: 92 , non-1: 132
Durability of SVR (N=224)
100%
Duration after SVR<6months
(N=3)
Follow up loss 
(N=65)
Non responder or relapse
(N=51, 14.9%)
Figure 1. Flow chart of patients.
follow-up period (Fig. 1). If SVR was achieved, there was no 
relationship between reappearance and the dose of either 
PEG-IFN or ribavirin. There were two patients who achieved the 
SVR but developed HCC during the follow-up period. Among 
them, one had liver cirrhosis before the treatment, the other 
patients with HCC was a 54-year-old heavy alcoholic. He did not 
have liver cirrhosis radiologically, but his aspartate aminotrans-
ferase-to-platelet ratio index (APRI) was 1.0 (Table 2). 
Figure 2 shows the numbers of patients who were followed up 
after SVR and the durability. SVR was maintained in all patients 
during the follow-up period, therefore there was no control group 
who had a reappearance. 
DISCUSSION
The standard therapy for HCV infection is the combination of 
PEG-IFN and ribavirin. According to previous studies, SVR was 
maintained up to 99-100%, and the achievement of the SVR was 
considered as cure.
9,16-20 
However, according to a recent Korean study, 73 out of 156 
patients treated successfully with interferon/peginterferon and 
ribavirin achieved the SVR. During the follow-up period of those 
73 patients with SVR, the HCV RNA reappeared in 8 patients 
(11%). In this Korean study, patients were enrolled from January 
2002 to October 2008, and the serum HCV RNA was measured 
quantitatively by real time polymerase chain reaction (RT-PCR) 
(ABI prism system, Applied Biosystems, USA).
21 However, the 
RT-PCR assay using the ABI prism system was used only in the 
past 5 years, hence in patients who were treated earlier, the HCV 
may be quantitatively measured by the HCV RNA assay with 
lower sensitivity and higher limit of detection than RT-PCR 
assay using ABI prism system. Therefore, some patients who had 
small quantities of HCV RNA, which could be detected with the 
current sensitive HCV RNA assay, may be assessed that they 
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Table 2. Characteristics of patients who developed HCC after 
achieving an SVR
Characteristics Patient 1 Patient 2
Sex M M
Age 54 57
Genotype 2a/2c 1b
Baseline ALT 50 47
Platelet count (×10
9/L) 156 116
APRI 1.0 1.1
HCV RNA titer (copies/mL) 4.2×10
4 1.1×10
7
BMI (kg/m
2) 20.9 23.0
RVR Yes No
Naїve/Re-treat Naїve Naїve
Liver cirrhosis No Yes
Heavy alcoholics Yes No
Peginterferon dose (%) 42.3 100.0
Ribavirin dose (%) 67.4 98.2
Duration of developing HCC after SVR 
(months)
29 4
ALT, alanine aminotransferase; APRI, aspartate aminotransferase- 
to-platelet ratio index; BMI, body mass index; HCV, hepatitis C
virus; HCC, hepatocellular carcinoma; RVR, rapid virological 
response; SVR, sustained virological response.
Figure 2. Durability of the SVR in the CHC patients 
treated with PEG-IFN plus ribavirin. The numbers in 
parentheses represent the numbers of patients who 
were followed up, which was 224 for a median 
duration of 18 months (range 6-60 months). The SVR 
was maintained in 100% of the patients during the 
follow-up.
sensitivity was used during the follow-up period, the HCV RNA 
could probably be detected in serum. This may be the cause for 
the higher reappearance rate detected in that study, compared to 
previous studies. Among the 8 patients who had reappearance of 
HCV in that study, only one patient had persistent viremia, 5 
patients had transiently positive HCV RNA, and 2 patients were 
followed-up.
21 It is possible that the transiently positive HCV 
RNA result may be false positive. Therefore, the reappearance 
rate can be considered as 1.4% (1/73). In a recent study, transient 
low levels of HCV RNA at single time points were detected in 
some serum samples during the follow-up, but they were all 
undetectable on retests.
19 Therefore, the authors reported that 
these transient positive tests probably represented false positive 
results.
20 In our study, we also experienced one transient postive 
HCV RNA result which was undetectable on retest. It is not 
known whether patients who become HCV RNA detectable 
during follow-up experienced reinfection or reappearance. 
Another Korean study recently reported that the reappearance 
rate after SVR was 7.4% (5/68). This higher reappearance rate 
also may be due to using HCV RNA assay with lower sensitivity 
in early treatment period.
22 
In our study, among the 292 patients who achieved the SVR in 
response to PEG-IFN and ribavirin combination therapy, 224 
were followed up for a median period of 18 months (range 6-60 
months). SVR was maintained in all patients (n=224, 100%), 
including patients who were treated with decreased doses of 
PEG-IFN or ribavirin, therefore the durability of SVR was as 
high as in previous studies. When patients were treated with 
decreased doses of PEG-IFN or ribavirin, they had lower SVR.
23 
After achievement of the SVR, however, we found no relationship 
between the treatment dose and reappearance. This suggests that, 
after achievement of the SVR, intensive follow-up is not needed 
in patients treated with lower doses of PEG-IFN or ribavirin than 
in patients who received sufficient doses.
In patients with CHC, achievement of the SVR has been 
associated with improvements in liver histology, as well as 
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patients with HCV-related cirrhosis, achievement of the SVR 
after IFN therapy was associated with reduction of liver-related 
mortality lowering both the risk of complications and HCC 
development.
13-15,24-26 However, in patients with advanced fibrosis 
or cirrhosis, achievement of the SVR cannot prevent completely 
the risk of HCC.
23,27,28
In our study, there were two patients who achieved the SVR 
but developed HCC during the follow-up period. Among them, 
one had liver cirrhosis before the treatment, so liver may undergo 
irreversible changes, leading to an elevated risk for carcinogenesis 
even when the HCV RNA has been disappeared in serum. 
The other patient was a alcoholic and showed APRI 1.0 that 
might suggest hepatic fibrosis. Thus, significant fibrosis 
and persistent liver damage due to alcohol were thought to be 
related with development of HCC, even when the HCV RNA was 
undetectable. Therefore, screening of HCC, with abdominal 
ultrasound and alfa-fetoprotein, are needed in patients with 
chronic hepatitis C with advanced fibrosis, as well as liver 
cirrhosis, even if they achieved the SVR. Future studies should 
identify the degree of liver fibrosis susceptible to increase the 
risk for development of HCC.
To summarize, previous studies reported that SVR after 
PEG-IFN and ribavirin combination therapy was maintained up 
to 99-100% during the long-term follow-up.
16-20  Our study 
showed that SVR was durable in all the CHC patients for a 
median follow-up of 18 months. However, screening test for 
HCC should be needed in the patients with SVR, particularly 
advanced fibrosis or cirrhosis.
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